Absorbed dose simulation of meta - 211 At-astato-benzylguanidine using pharmacokinetics of 131 I-MIBG and a novel dose c
- PDF / 2,876,588 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 18 Downloads / 156 Views
ORIGINAL ARTICLE
Absorbed dose simulation of meta‑211At‑astato‑benzylguanidine using pharmacokinetics of 131I‑MIBG and a novel dose conversion method, RAP Tetsuya Sakashita1 · Shigeki Watanabe1 · Hirofumi Hanaoka2 · Yasuhiro Ohshima1 · Yoko Ikoma3 · Naoyuki Ukon4 · Ichiro Sasaki1 · Tatsuya Higashi3 · Tetsuya Higuchi5 · Yoshito Tsushima5 · Noriko S. Ishioka1 Received: 19 February 2020 / Accepted: 2 November 2020 © The Japanese Society of Nuclear Medicine 2020
Abstract Objective We aimed to estimate in vivo 211At-labeled meta-benzylguanidine (211At-MABG) absorbed doses by the two dose conversion methods, using 131I-MIBG biodistribution data from a previously reported neuroblastoma xenograft model. In addition, we examined the effects of different cell lines and time limitations using data from two other works. Methods We used the framework of the Monte Carlo method to create 3200 virtual experimental data sets of activity concentrations (kBq/g) to get the statistical information. Time activity concentration curves were produced using the fitting method of a genetic algorithm. The basic method was that absorbed doses of 211At-MABG were calculated based on the medical internal radiation dose formalism with the conversion of the physical half-life time of 131I to that of 211At. We have further improved the basic method; that is, a novel dose conversion method, RAP (Ratio of Pharmacokinetics), using percent injected dose/g. Results Virtual experiments showed that 211At-MABG and 131I-MIBG had similar properties of initial activity concentrations and biological components, but the basic method did not simulate the 211At-MABG dose. Simulated 211At-MABG doses from 131I-MIBG using the RAP method were in agreement with those from 211At-MABG, so that their boxes overlapped in the box plots. The RAP method showed applicability to the different cell lines, but it was difficult to predict long-term doses from short-term experimental data. Conclusions The present RAP dose conversion method could estimate 211At-MABG absorbed doses from the pharmacokinetics of 131I-MIBG with some limitations. The RAP method would be applicable to a large number of subjects for targeted nuclide therapy. Keywords Targeted alpha therapy · Dose conversion · Biodistribution · MIRD calculation · Monte Carlo simulation
Introduction Electronic supplementary material The online version of this article (https://doi.org/10.1007/s12149-020-01548-6) contains supplementary material, which is available to authorized users. * Tetsuya Sakashita [email protected] 1
2
Quantum Beam Science Research Directorate, National Institutes for Quantum and Radiological Science and Technology, 1233 Watanuki‑machi, Takasaki 370‑1292, Japan Department of Bioimaging Information Analysis, Gunma University Graduate School of Medicine, 3‑39‑22 Showa, Maebashi 371‑8511, Japan
Radionuclides emit various ionizing radiations depending on the different types of radioactive decay and provide many benefits in nuclear medicine therapy and diagnosis. 3
Depart
Data Loading...
